Great news!

https://www.bioasis.us/bioasis-announces-allowances-of-patent-applications-in-the-u-s-and-europe-relating-to-xb3-platform-technology-and-key-therapeutic-indications/

"U.S. Patent Office and European Patent Office issue allowances of patent applications relating to iduronate-2-sulfatase (“IDS”) polypeptide/xB3 conjugates. European Patent Office issues allowance of patent application relating to trastuzumab/xB3 conjugates including xB3-001, Bioasis’ lead product in development for the treatment of HER2+ breast cancer brain metastases"